Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29163766 | 0.84 | GABRA5 (0.53) | SLC6A2SLC6A4SLC6A3SLC6A1GABRA5 | |
| Trifluoroacetic Acid SCHEMBL28325251 | 0.84 | GABRA5 (0.53) | SLC6A2SLC6A4SLC6A3SLC6A1GABRA5 | |
| Trifluoroacetic Acid SCHEMBL20494145 | 0.84 | GABRA5 (0.53) | SLC6A2SLC6A4SLC6A3SLC6A1GABRA5 | |
| Trifluoroacetic Acid SCHEMBL15019572 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL29037139 | 0.81 | CPN1 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6SLC6A1 | |
| Trifluoroacetic Acid SCHEMBL29091006 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL22749353 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL1663586 | 0.81 | SLC6A12 (0.53) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Acetic Acid SCHEMBL72856 | 0.79 | SLC6A1 (0.40) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL22557721 | 0.79 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-117062814-A | Compounds that rapidly accelerate fibrosarcoma protein degradation and related methods of use | 阿维纳斯运营公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4204418-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-1889836-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | EISAI R&D MAN CO LTD (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-2058302-B1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| CN-101198590-B | pyridine derivative and pyrimidine derivative (3) | EISAI R&D MAN CO LTD | 2012-05-09 | — | — | CN | disclosed |
| CN-101454286-B | Process for producing phenoxypyridine derivative | EISAI R&D MAN CO LTD | 2011-07-20 | — | — | CN | disclosed |
| US-7855290-B2 | N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7790885-B2 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | MATSUSHIMA TOMOHIRO | 2010-03-25 | — | — | US | disclosed |
| CN-101454286-A | Process for producing phenoxypyridine derivative | EISAI R&D MAN CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-2058302-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
| CN-101198590-A | Novel pyridine derivative and pyrimidine derivative (3) | EISAI R&D MAN CO LTD (JP) | 2008-06-11 | — | — | CN | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | SLC6A2 4722/4885SLC6A4 4649/4885SLC6A3 4495/4885 |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | CRBN, RBX1, ARAF | SLC6A2 4699/4885SLC6A4 4643/4885SLC6A3 4503/4885 |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | SLC6A2 4722/4885SLC6A4 4649/4885SLC6A3 4495/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | SLC6A2 3982/4885SLC6A4 3056/4885SLC6A3 2049/4885 |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | HGF, MET, HDGF | SLC6A2 3584/4885SLC6A4 2659/4885SLC6A3 1571/4885 |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | FIP1L1, SKP1, TET2 | SLC6A2 3793/4885SLC6A4 3040/4885SLC6A3 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.